nk1999
12 Sep 2016
Mail- Midas "Biotech group Redx Pharma floated on AIM in March 2015 at 85p. Today the stock is trading at 26¾p. Yet the company has done nothing obviously wrong and it is backed by heavyweight investors including Aviva, Legal & General and Jon Moulton, the super-rich private equity veteran.The company has a large pipeline of potential drugs, several of which are at an exciting stage of development. So, if all goes according to plan, the shares should rise considerably from current levels.;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;Despite regional support and its licensing strategy, Murray may well need to issue more shares to fund growth. In March, the firm raised £10million in an equity placing at 35p and it now has £14million in the bank. But analysts predict that Murray will be back for more.Midas verdict: Redx is at an early stage in its evolution and the share price performance has been poor. There is also the chance that Murray will come cap in hand to investors over the next year. Long-term, however, this company could prove a rewarding investment and at 26¾p, the shares are a bargain."Read more: [link] Follow us: @MailOnline on Twitter | DailyMail on Facebook
BassCadet
05 Jul 2016
Re: Why it's a buy Hi Our Haven.May I ask where the 9p comes from please? I don't see any previous notes.
Our Haven
25 Apr 2016
Re: Why it's a buy It could be worth a punt now though according to the previous note you should wait until it is 9p. Thanks Pendil for the information, think there may be some more downside so will wait a little longer, hope not to miss the boat though.
pendil
07 Nov 2015
Why it's a buy This is an early stage drug development company but I believe a better bet than most for the following reasons:Their proprietary technology involves altering existing drugs. This seems to give a high probability that the new compounds will be both non-toxic and effective. All that remains is then then to establish that they are more effective than the existing drugs.this means they have identified I think 13 development candidates, at least 5 of which have advanced to pre-clinical proof of concept stage, mostly in the fields of oncology and anti-infectives.They have entered into 5 commercial partnerships including with Astra Zeneca and the NHS. This not only provides external validation of the technology but shares the cost of development and provides the potential for early income in the form of milestone payments (at the expense of course of sharing ultimate revenues).They have also been and continue to be very successful in obtaining grant funding for the research, such that despite the number of candidates they are progressing, cash burn was only about £4m for the last half year.It probably only needs one of their candidates to be a quite minor success to justify the current share price. More than that and the price will be a multiple of the current price in a few years’ time, assuming someone like Astra Zeneca does not snap it all up first.In summary, what distinguishes them from other early stage drug companies:• Number of drug candidates (not all eggs in one basket)• number of commercial partnerships• cost effective development programme.All this makes me a very happy holder.
numberbiter
27 Oct 2015
Reality This is a good company carrying out vital research that the large pharma companies cannot be bothered to do. But it is still in the start up stage and has no revenue other than the grants it receives. Consequently, the current valuation of 91p is miles away from reality. The reality is that this company will have no effective value until one of the drugs it is researching gains a licence. In terms of odds, the current price of 90p is like backing a horse at 50/1 when the odds you should be getting is 500/1. That's not to say the horse cannot win, but rather it should not be backed until it shows some form.
pendil
02 Jun 2015
New anti-infective Impressive news flow. Only tipped by IC last Friday and now they announce a new anti-infective in pre-clinical trails. They do seem to have a super efficient technology to identify new drug candidates. With the number of potential blockbusters here the potential upside looks very significant.
quackers1
11 May 2015
RNS -Advanced Cancer Drug Liverpool drug development company Redx has reached pre-clinical proof of concept stage with an advanced cancer drug which has the potential to tackle hard-to-treat cancers, including pancreatic, breast and head and neck cancer.This represents the fifth programme to have advanced through Redx’s innovative development pipeline to pre-clinical proof of concept and has been achieved in just over 12 months, from a standing start.Only one other similar treatment exists, which is currently in clinical development.The novel, potent small molecule porcupine inhibitor targets the Wnt pathway, an embryonic signalling pathway that is implicated in the maintenance of cancer stem cells in multiple cancer types.These are associated with tumorigenesis, metastasis, recurrence and resistance in cancer.It will have the potential to be taken orally by patients as a once daily dose.Redx chief executive Dr Neil Murray said: “We’re very pleased to have reached pre-clinical proof of concept with this very promising programme.“The cancers it has the potential to tackle are some of the most hard-to-treat.“Consequently, we are delighted to be making steps on the journey to address the challenge and to have developed this novel porcupine inhibitor which will help to tackle these areas of high unmet need.”He added: “Redx’s access to primary patient sample and extensive niche expertise in cancer stem cell assays, have proved particularly helpful in this instance.“This programme also demonstrates Redx’s capability to accelerate development timelines - taking a programme to proof of concept in just over 12 months from a standing start.“We look forward to continuing to develop our porcupine assets and assess their potential as a treatment for pancreatic, triple negative breast, and head and neck cancers.”
